Axogen to Acquire BioCircuit Technologies for $200M to Expand Peripheral Nerve Repair Portfolio

Alachua and Tampa, FL, September 10, 2026 (Axogen) -- Axogen has entered into a definitive agreement to acquire privately held medical device company BioCircuit Technologies for $200 million in cash. The acquisition adds NerveTape, the first FDA-approved sutureless peripheral nerve repair device, to Axogen’s portfolio and is expected to broaden its addressable market. The transaction is expected to close in the fourth quarter of 2026, subject to customary conditions, including the completion of BioCircuit’s planned spin-out of its unrelated electronics business.

Read full article here.